Cite
HARVARD Citation
Bowman, S. et al. (2022). Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. Lancet. 399 (10320), pp. 161-171. [Online].